{"id":3756,"date":"2021-04-09T08:00:00","date_gmt":"2021-04-09T06:00:00","guid":{"rendered":"https:\/\/ibtherapeutics.com\/sv\/mfn_news\/infant-bacterial-therapeutics-publicerar-arsredovisning-for-2020\/"},"modified":"2023-10-02T13:51:41","modified_gmt":"2023-10-02T11:51:41","slug":"infant-bacterial-therapeutics-publicerar-arsredovisning-for-2020","status":"publish","type":"mfn_news","link":"https:\/\/ibtherapeutics.com\/sv\/pressmeddelanden\/infant-bacterial-therapeutics-publicerar-arsredovisning-for-2020\/","title":{"rendered":"Infant Bacterial Therapeutics publicerar \u00e5rsredovisning f\u00f6r 2020"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/strong><\/div>\n<div>\n<p>Infant Bacterial Therapeutics AB (publ) publicerar idag \u00e5rsredovisningen f\u00f6r r\u00e4kenskaps\u00e5ret 2020.<\/p>\n<p>\u00c5rsredovisningen finns tillg\u00e4nglig p\u00e5 IBTs hemsida\u00a0<strong>ibtherapeutics.com\u00a0<\/strong>under avsnittet \u201dInvesterare &amp; Media \u2013 Finansiella rapporter\u201d och distribueras i tryckt form till de som har best\u00e4llt den. Den kan best\u00e4llas fr\u00e5n IBTs kontor via info@ibtherapeutics.com.<\/p>\n<p><strong><em>Om Infant Bacterial Therapeutics AB<\/em><\/strong><\/p>\n<p>Infant Bacterial Therapeutics AB (publ) (\u201cIBT\u201d) \u00e4r ett l\u00e4kemedelsf\u00f6retag med en produkt i klinisk forskningsfas, vars vision \u00e4r att utveckla l\u00e4kemedel som p\u00e5verkar sp\u00e4dbarns mikrobiom och d\u00e4rigenom kunna f\u00f6rebygga eller behandla s\u00e4llsynta sjukdomar som drabbar sp\u00e4dbarn.<\/p>\n<p>IBT \u00e4r f\u00f6r n\u00e4rvarande inriktat p\u00e5 att utveckla l\u00e4kemedelskandidaten IBP-\u00ad9414 som syftar till att f\u00f6rebygga nekroti\u00adserande enterokolit (\u201dNEC\u201d) samt att f\u00f6rb\u00e4ttra s\u00e5 kallad <em>feeding tolerance<\/em> hos f\u00f6r tidigt f\u00f6dda barn. IBP-9414 inneh\u00e5ller <em>Lactobacillus reuteri<\/em> som aktiv substans, vilket \u00e4r en human bakteriestam som \u00e5terfinns naturligt i br\u00f6stmj\u00f6lk. I portf\u00f6ljen finns \u00e4ven ett ytterligare projekt, IBP\u00ad-1016, f\u00f6r behandling av gast\u00adroschisis, en allvarlig och s\u00e4llsynt sjukdom som drabbar sp\u00e4dbarn. Genom utvecklingen av dessa l\u00e4kemedel har IBT m\u00f6jlighet att tillfredsst\u00e4lla medicinska behov d\u00e4r det idag inte finns n\u00e5gra tillg\u00e4ngliga behandlingar.<\/p>\n<p>Infant Bacterial Therapeutics AB (\u201dIBT\u201d) \u00e4r ett publikt bolag med s\u00e4te i Stockholm. Bolagets aktier av serie B handlas pa\u030a Nasdaq Stockholm, Mid Cap (IBT B).<\/p>\n<p><strong>F\u00f6r mer information, v\u00e4nligen kontakta <\/strong><\/p>\n<p>Staffan Str\u00f6mberg, VD<br \/>Daniel Mackey CFO<br \/>Infant Bacterial Therapeutics AB<br \/>Bryggargatan 10<br \/>111 21 Stockholm<br \/>Telefon: +46 70 670 1226<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r7rcub1W6Z1Icqe3hUK8iYN_tz0mloByV_aSEJBqpZDtdkx8lJZ4Z70Do52Squc0y0TWHZK0xoGuWamx1L03wUVgdQqkeF56SPHPq-BTJnY=\" target=\"_blank\" title=\"\" rel=\"nofollow noopener\"><u>info@ibtherapeutics.com<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=99o8ei8doR3szI0X2s4GSE6Q5CKSAZTRWwrMCL8LkQNp8jxpCQqvLHgqwJxwAaF6zdX2y1KzEjp7152CmW0KcRGekz6WIHqKPncv71MQ_zo=\" target=\"_blank\" title=\"\" rel=\"nofollow noopener\"><u>www.ibtherapeutics.com<\/u><\/a><\/p>\n<p><strong>Offentligg\u00f6rande<\/strong><\/p>\n<p>Informationen l\u00e4mnades f\u00f6r offentligg\u00f6rande den 9 april 2021, kl. 08.00 (CET).<\/p>\n<p>\u00a0<\/p>\n<p>\n        <\/div>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/bd281759-cd50-4cbb-99b2-e6b2e8a912fd\" target=\"_blank\" rel=\"nofollow noopener\">IBTAR2020SWE 20200407.pdf.zip<\/a><br \/><a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/c9476acd-a01e-47bd-8f59-b50f6b877526\" target=\"_blank\" rel=\"nofollow noopener\">PR 20210409 AR SWE<\/a><br \/><a href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/e5765ac5-16ed-4ac0-baa8-a88458a755b5\" target=\"_blank\" rel=\"nofollow noopener\">IBTAR2020SWE 20200407<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment\"><a class=\"mfn-attachment-link\" href=\"https:\/\/storage.mfn.se\/a\/infant-bacterial-therapeutics\/78b46e4f-5dad-4596-8303-baf51ceef778\/ibt-arsredovisning-2020.pdf\"><span class=\"mfn-attachment-icon\"><img alt=\"Infant Bacterial Therapeutics publicerar \u00e5rsredovisning f\u00f6r 2020\" src=\"https:\/\/storage.mfn.se\/a\/infant-bacterial-therapeutics\/78b46e4f-5dad-4596-8303-baf51ceef778\/ibt-arsredovisning-2020.pdf?type=jpg\"><\/span>IBT \u00c5rsredovisning 2020<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Infant Bacterial Therapeutics AB (publ) publicerar idag \u00e5rsredovisningen f\u00f6r r\u00e4kenskaps\u00e5ret 2020. \u00c5rsredovisningen finns tillg\u00e4nglig p\u00e5 IBTs hemsida\u00a0ibtherapeutics.com\u00a0under avsnittet \u201dInvesterare &amp; Media \u2013 Finansiella rapporter\u201d och distribueras i tryckt form till de som har best\u00e4llt den. Den kan best\u00e4llas fr\u00e5n IBTs kontor via info@ibtherapeutics.com. Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ) (\u201cIBT\u201d) \u00e4r [&hellip;]<\/p>\n","protected":false},"template":"","_links":{"self":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3756"}],"collection":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=3756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}